Post-exposure prophylaxis (PEP) to varicella-zoster virus (VZV)
These hypothetical case studies are sponsored by Kamada Inc. All rights reserved. These case studies are intended for the use and education of the U.S. Health Care Providers.
This activity will explore optimal therapeutic strategies for managing exposure to varicella-zoster virus, with a focus on:
• Clinical Implications: Understanding the impact of varicella-zoster virus exposure in high-risk patients.
• Targeted Therapeutic Strategies: Reducing the risk of severe disease and complications in vulnerable groups, including immunocompromised patients.
• Outbreak Awareness: As outbreaks still occur, highlighting the continued relevance of varicella, even after decades of inclusion in the U.S. childhood vaccination schedule.
• Advances in Prophylactic Strategies: Emphasizing the availability of an FDA-approved, readily available prophylactic option.
This case study is promotional in nature and includes information on Kamada's products.
The information presented is not intended as medical advice. The responsibility for patient care resides with the healthcare professional based on their professional license, experience, and knowledge of the individual patient.
Please refer to the approved product labeling for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events. For Important Safety Information (ISI), please refer to the next page. Within The United States, full prescribing information is available here.
https://dailymed.nlm.nih.gov/dailymed/druglnfo.cfm?setid=f367f996-aafa-4b8b-8cb4-63a009cd2015
• Clinical Implications: Understanding the impact of varicella-zoster virus exposure in high-risk patients.
• Targeted Therapeutic Strategies: Reducing the risk of severe disease and complications in vulnerable groups, including immunocompromised patients.
• Outbreak Awareness: As outbreaks still occur, highlighting the continued relevance of varicella, even after decades of inclusion in the U.S. childhood vaccination schedule.
• Advances in Prophylactic Strategies: Emphasizing the availability of an FDA-approved, readily available prophylactic option.
This case study is promotional in nature and includes information on Kamada's products.
The information presented is not intended as medical advice. The responsibility for patient care resides with the healthcare professional based on their professional license, experience, and knowledge of the individual patient.
Please refer to the approved product labeling for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events. For Important Safety Information (ISI), please refer to the next page. Within The United States, full prescribing information is available here.
https://dailymed.nlm.nih.gov/dailymed/druglnfo.cfm?setid=f367f996-aafa-4b8b-8cb4-63a009cd2015
Steering committee
Hayley A. Gans, MD
Clinical Professor, Pediatrics - Infectious Diseases
Stanford University School of Medicine
Glenn R. Markenson, MD
Professor, Obstetrics & Gynecology
Boston University Chobanian & Avedisian School of Medicine
Case modules
PRO-VAR-1202-v1
Meredith, a 32-year-old woman, scheduled for a cesarean section
Meredith, a 32-year-old woman, scheduled for a cesarean section
PRO-VAR-1211-v1
Sarah, 8-year-old girl with a history of sJIA
Sarah, 8-year-old girl with a history of sJIA
PRO-VAR-1205-v1
Julia, a pregnant woman with confirmed varicella exposure
Julia, a pregnant woman with confirmed varicella exposure
PRO-VAR-1209-v1
Gary, a 28-week preterm infant currently in the NICU
Gary, a 28-week preterm infant currently in the NICU
.png)
PRO-VAR-1208-v1
Emma, a 6-year-old girl with a history of AML
Emma, a 6-year-old girl with a history of AML
PRO-VAR-1210-v1
Joe, a 14-year-old boy underwent a kidney transplant 5 months ago
Joe, a 14-year-old boy underwent a kidney transplant 5 months ago
Indication and Usage
VARIZIG is a Varicella Zoster Immune Globulin (Human) indicated for post-exposure prophylaxis in high-risk individuals. High-risk groups include: immunocompromised children and adults, newborns of mothers with varicella shortly before or after delivery, premature infants, neonates and infants less than one year of age, adults without evidence of immunity, pregnant women.
VARIZIG administration is intended to reduce the severity of varicella.
Important Safety Information
VARIZIG contains trace amounts of IgA. Individuals known to have anaphylactic or severe systemic (hypersensitivity) reactions to human immune globulin preparations should not receive VARIZIG.
IgA-deficient patients with antibodies against IgA and a history of hypersensitivity may have an anaphylactoid reaction. Thrombotic events may occur during or following treatment with immune globulin products. Administer VARIZIG intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, only administer VARIZIG if the expected benefits outweigh the potential risks. Severe hypersensitivity reactions may occur following VARIZIG administration. In case of hypersensitivity, discontinue administration of VARIZIG immediately and provide appropriate treatment. Because VARIZIG is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease agent, and, theoretically, the Creutzfeldt-Jakob disease agent.
The most serious adverse drug reactions observed in clinical trials for all subjects and patients include pyrexia, nausea, and vomiting. The most common adverse drug reactions observed in clinical trials for all subjects and patients were injection site pain, headache, chills, fatigue, rash, and nausea.
Please see full Prescribing Information for complete prescribing details.
To report SUSPECTED ADVERSE REACTIONS, contact Kamada at pharmacovigilance@kamada.com or 1-(866)-916-0077 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
VARIZIG is a registered trademark of Kamada Ltd. Kamada Inc., 221 River St, Hoboken, NJ 07030. Tel. 1-833-779-2614 ©2024 Kamada Inc.
VARIZIG is a Varicella Zoster Immune Globulin (Human) indicated for post-exposure prophylaxis in high-risk individuals. High-risk groups include: immunocompromised children and adults, newborns of mothers with varicella shortly before or after delivery, premature infants, neonates and infants less than one year of age, adults without evidence of immunity, pregnant women.
VARIZIG administration is intended to reduce the severity of varicella.
Important Safety Information
VARIZIG contains trace amounts of IgA. Individuals known to have anaphylactic or severe systemic (hypersensitivity) reactions to human immune globulin preparations should not receive VARIZIG.
IgA-deficient patients with antibodies against IgA and a history of hypersensitivity may have an anaphylactoid reaction. Thrombotic events may occur during or following treatment with immune globulin products. Administer VARIZIG intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, only administer VARIZIG if the expected benefits outweigh the potential risks. Severe hypersensitivity reactions may occur following VARIZIG administration. In case of hypersensitivity, discontinue administration of VARIZIG immediately and provide appropriate treatment. Because VARIZIG is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease agent, and, theoretically, the Creutzfeldt-Jakob disease agent.
The most serious adverse drug reactions observed in clinical trials for all subjects and patients include pyrexia, nausea, and vomiting. The most common adverse drug reactions observed in clinical trials for all subjects and patients were injection site pain, headache, chills, fatigue, rash, and nausea.
Please see full Prescribing Information for complete prescribing details.
To report SUSPECTED ADVERSE REACTIONS, contact Kamada at pharmacovigilance@kamada.com or 1-(866)-916-0077 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
VARIZIG is a registered trademark of Kamada Ltd. Kamada Inc., 221 River St, Hoboken, NJ 07030. Tel. 1-833-779-2614 ©2024 Kamada Inc.